EMT-inducing transcription factors (EMT-TFs) of the SNAIL, TWIST and ZEB families are frequently reactivated during tumorigenesis. In carcinoma, in addition to promoting metastasis, they favor neoplastic transformation of epithelial cells by enabling escape from failsafe programs and providing cells with stem-like properties. We recently unveiled different functions and regulatory mechanisms of EMT-TFs in melanoma, a highly metastatic neural crestderived cancer. A switch in expression is observed from SNAIL2 and ZEB2, which are expressed in melanocytes and behave as oncosuppressive proteins to TWIST1 and ZEB1, which are aberrantly reactivated in melanoma and foster neoplastic transformation of melanocytes. This reversible switch in EMT-TF expression driven by a MEK-ERK-FRA1 pathway represents a novel independent factor of poor prognosis in patients with malignant melanoma. We herein discuss cell type specific biological functions of EMT-TFs in terms of cancer cell plasticity.
Epithelial-mesenchymal transition (EMT) is an essential program during embryonic development. EMT drives the reversible reprogramming of polarized epithelia into mesenchymal cells by providing motility properties. This cellular plasticity process, tightly regulated in response to microenvironmental signals, is driven by a network of embryonic EMT-inducing transcription factors (EMT-TFs) mainly represented by the SNAIL, TWIST and ZEB protein families. Aberrant reactivation of this embryonic process is frequently observed during tumorigenesis and it has been particularly studied in tumors of epithelial origin, carcinomas [1, 2] . Primarily implicated in the invasiondissemination-metastasis cascade [3, 4, 5] , aberrant expression of EMT-TFs was also shown to foster malignant
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transformation. EMT-TF's oncogenic potential mainly relies on their ability to promote escape from oncogeneinduced senescence and apoptosis by interfering with p53 and RB tumor suppressor pathways [6, 7, 8, 9] . These factors additionally provide cells with stem-like properties [10, 11] . While aberrant reactivation of EMT in epithelial cells is clearly oncogenic, functions of EMT-TFs in non-epithelial cells are largely unknown.
Based on the crucial role of EMT in the embryonic neural crest [2] , we recently analyzed expression and function of EMT-TFs in melanocytes and melanoma, a highly aggressive skin cancer originating from the neural crest. Malignant melanoma represents one of the deadliest cancer types at the metastatic stage. Mutually exclusive gain-of-function mutations are observed in melanoma in oncogenes such as NRAS (15-25%) or, most frequently, in BRAF (~50%). These mutations lead to the constitutive activation of the downstream MEK-ERK signaling pathway, providing tumor cells with proliferation and survival advantages. A substitution of glutamic acid for valine at position 600 (V600E) in the serine/threonine protein kinase BRAF is the most common mutation in BRAF in melanoma. BRAFV600E mutations are also found in up to 80% of human nevi, benign melanocytic lesions that can remain unchanged for decades. Melanoma progression involves transition from a radial to a vertical growth phase, characterized by invasion into the dermis and subcutaneous tissue. Although the term "EMT" cannot be formally defined, differentiated melanocytes express Ecadherin and loss of this epithelial marker, a hallmark of EMT in carcinoma, is observed in late-stage melanoma that will invariably metastasize [12] .
We have unraveled different roles for EMT-TFs in melanoma compared to carcinoma [13] . We showed that during melanomagenesis, a reversible switch from a tumorsuppressive to an oncogenic EMT-TF expression pattern occurs. SNAIL2 and ZEB2 transcription factors drive a melanocytic differentiation program and behave as Figure 1 . Schematic of EMT-TF expression at different stages of melanoma progression. Development of malignant melanoma is a multistep process relying on a series of genetic alterations. A first oncogenic event (such as BRAF/NRAS mutation) triggers melanocytes proliferation, which generally induces senescence and formation of nevi (benign lesions). ZEB2 and SNAIL2 are still detected in nevi, presumably because of various negative feedback mechanisms suppressing MEK-ERK signaling. While acquisition of secondary genetic events is required for transition to malignant cells, progression to primary melanoma does not always involve a nevus stage. Elevation of the MEK-ERK signaling pathway (as evidenced by the level of phosphorylated ERK, P-ERK) in primary melanomas results in a tendency towards loss of ZEB2 and SNAIL2 and gain of ZEB1 and TWIST1 expression. Melanoma cells can then invade the dermis, enter the blood vessels and metastasize. Only a few millimetres of dermal invasion are needed for the tumor to spread. Of note, the gradients in ZEB2/SNAIL2 and ZEB1/TWIST1 expression are correlated with E-cadherin and P-ERK gradients in both primary tumors and lymph node metastases.
oncosuppressive proteins, whilst TWIST1 and ZEB1 possess oncogenic properties. We herein discuss the biological implications of these cell type specific functions for EMT-TFs in the context of cancer cell plasticity.
Expression of EMT inducers is considered to be transient during embryogenesis, EMT becoming latent in most adult tissues. Detection of EMT-TFs in the adult epithelial lineage mainly results from their aberrant reactivation in pathological conditions, such as organ fibrosis [14] and tumorigenesis [1] . EMT-TF expression analyses in normal human skin samples unexpectedly showed that SNAIL2 and ZEB2 are expressed in differentiated melanocytes, while TWIST1 and ZEB1 are not detected. As expected, adjacent epidermal cells were negative for these factors. Accordingly, endogenous expression of EMT-TFs has been described in other normal adult differentiated cell types (neurons, lymphocytes or endothelial cells), suggesting that their major roles in cell differentiation and normal tissue homeostasis may not be exclusively restricted to embryonic development.
More importantly, during the transition from nevi to malignant melanoma, a progressive loss of ZEB2/SNAIL2 expression and a gain in TWIST1/ZEB1 was observed in a melanoma progression series (Figure 1 ). Metastasis-free survival data analyses of melanoma patients further indicated that this switch from ZEB2/SNAIL2 to TWIST1/ZEB1 constitutes a major factor of poor prognosis. This first comprehensive study of the whole EMT-TF network in melanomas provides evidence consistent with other independent melanoma series showing either activation of TWIST1 [15] , loss of ZEB2 [16] or SNAIL2 [17] . Moreover, within primary melanoma lesions, opposite gradients in the expression of ZEB2/SNAIL2 and TWIST1/ZEB1 from superficial to deep sites correlated with two major attributes of melanoma progression and aggressivity: namely MAPK pathway activation (as evidenced by the level of phosphorylation of the ERK kinase, resulting from BRAF or NRAS mutations and from additional mechanisms enabling escape of ERK from negative feedback loops); and E-cadherin loss, a hallmark of vertical growth and invasion into the dermis in aggressive stages. While SNAIL2/ZEB2 were paradoxically co-expressed with E-cadherin in normal melanocytes and senescent melanocytes from nevi, loss of E-cadherin expression in deep site of primary tumors correlated with strong ZEB1/TWIST1 activation ( Figure  1 ). Therefore, in contrast to carcinoma where aberrant reactivation of EMT-TFs fosters neoplastic cell transformation and invasion, malignant melanoma progression is instead associated with a switch in the composition of EMT-TF expression from ZEB2 High /SNAIL2 High /ZEB1 Low / TWIST1 Low to ZEB2 Low / SNAIL2 Low /ZEB1 High / TWIST1 High .
Further in vitro analyses showed that EMT-TF reprogramming is directly regulated by the MEK-ERK signaling pathway. While activation of BRAF is sufficient to induce the switch in EMT-TF expression profile in normal melanocytes, inhibition of the MAPK pathway with BRAF/MEK inhibitors induces the opposite reprogramming in human melanoma cells. This reversible switch in EMT-TF expression is controlled downstream of ERK by a member of the AP-1 complex, the FRA1 (FOS related 1) transcription factor. Inter-regulations between FRA1 and EMT-TFs were recently shown to play a critical role in breast carcinoma cell plasticity [18, 19] . More importantly, alteration of the switch (through inhibition of ZEB1/TWIST1/FRA1 or ectopic expression of ZEB2/SNAIL2) is sufficient to impair BRAF-dependent melanocyte transformation both in vitro and in vivo in xenograft experiments. Therefore, while ZEB1 and TWIST1 harbor oncogenic activities in melanoma, ZEB2 and SNAIL2 act as oncosuppressive proteins in this specific neural-crest derived lineage, in contrast to carcinoma.
Interestingly the ZEB2/SNAIL2 "differentiation pattern" of EMT-TF expression is reconstituted in cortical areas of lymph node metastases, and correlates with Ecadherin and phospho-ERK gradients, in a similar way as described in primary tumors (Figure 1 ). This may reflect early metastatic dissemination to lymph nodes, followed by similar EMT-TF reprogramming as seen in primary tumors, as suggested in epithelial tumors [20] . ZEB1 high /TWIST1 high melanoma cells from medullar regions of lymph nodes may then fuel additional metastatic dissemination waves. Alternatively, highly plastic melanoma cells may redifferentiate at the metastatic site, as suggested in the model of carcinoma metastasis, where re-differentiation is crucial for metastatic colonization [21] . Reversible EMT-MET cycles would thus be required for the completion of the metastatic process and ZEB2/SNAIL2 might, in this model, equally contribute to the high metastatic propensity of melanomas as previously suggested [22] . These data highlight the major role of tumor cell plasticity in both melanomas and carcinomas.
A tumor-suppressive role for SNAIL2 and ZEB2 in melanoma was unexpected, although such an activity was suggested for Zeb2 mRNA through the activation of PTEN expression [16] . The fact that both factors are normally expressed in human melanocytes fits with the idea that their oncosuppressive function may rely on their specific role in melanocyte differentiation. Melanoma phenotypic plasticity is dynamically regulated by the microphthalmiaassociated transcription factor MITF, the master regulator of melanocyte development [23] . According to the rheostat model proposed by Colin Goding, high MITF expression maintains differentiated status of melanocytes, intermediate MITF expression sustains proliferation, while low MITF levels generate invasive and slow-proliferating cells with tumor-initiating properties [24] . Our data suggest that antagonistic functions of EMT-TFs in melanoma rely on their opposing effects on MITF expression and melanocyte differentiation. Gene expression profiles of BRAF-activated melanocytes indeed revealed that ZEB2/SNAIL2 activate MITF and cause a melanocyte differentiation gene signature, while ZEB1/TWIST1 repress MITF and generate an invasion-associated gene signature [13] . Such a crosstalk between MITF and EMTTFs is supported by studies in mutant mice and humans. MITF mutation results in various degrees of pigmentation defects in mice and is associated with Waardenburg syndrome type 2 in humans, a disorder with pigmentary abnormalities and sensorineural deafness. Snai2 depletion in mice alters commitment of neural crest cells into melanoblasts, leading to skin depigmentation on the ventral body and a white forehead [25] , and SNAI2 homozygous deletions are found in some patients with Piebaldism and Waardenburg syndrome type 2D [26] . Moreover, SNAIL2 was shown to correlate with MITF expression during melanoma progression [17] . In a similar way, Zeb2 depletion in mice results in neural crest cell defects [27] and ZEB2 heterozygous mutations are observed in Mowat-Wilson syndrome, a mental retardation syndrome characterized by multiple congenital malformations, including Hirschsprung disease [28] . In contrast with ZEB2/SNAIL2, but consistently with our model, ZEB1 was shown to repress MITF and alter pigmentation in mice retina [29] .
This implies that, depending on their respective role on cell differentiation in a given cell type, EMT-TFs may act either as oncoproteins or tumor suppressors. Additional work will be required to precisely unravel the molecular mechanisms mediating antagonistic functions for ZEB2 and ZEB1 in specific cell types, and therefore decipher the basis for the specificity of the tumor suppressor role of EMT-TF. Of note, targeted disruption of the Zeb2 or Zeb1 genes in mice revealed differences in expression during embryonic development, with specific spatio-temporal regulation and non-redundant functions in certain tissues (such as the lymphoid system) [30] . Moreover, Zeb2 knockout in the mouse embryo results in increased ZEB1 expression in paraxial mesoderm and in neural folds, supporting our results that ZEB2 can inhibit ZEB1 expression in the melanocyte lineage. How can ZEB2 repress ZEB1 in this specific cell type but not in a mesenchymal context? One hypothesis to explain the antagonistic functions between ZEB1 and ZEB2 could rely on differential recruitment of co-factors, as previously [31, 32] : both ZEB1 and ZEB2/SIP1 (SMAD interacting protein) bind SMADs, but while ZEB1 acts synergistically to activate transcription through binding to p300 coactivator, ZEB2 has the opposite role through binding the CtBP co-repressor.
In conclusion, these data highlight crucial roles for TWIST1 and ZEB1 in promoting cell dedifferentiation and plasticity of non-epithelial cells. By regulating MITFdependent phenotype switching, deregulation of the EMT-TF network contributes to malignant progression of melanoma. Therefore, targeting the EMT-TF network represents an attractive treatment strategy for metastatic melanomas that invariably develop resistance to BRAFV600 targeted therapy.
